20 Myths About Personalized Depression Treatment: Busted > 자유게시판

본문 바로가기

고객센터

패키지로 새로운 내일을 준비합니다

 

20 Myths About Personalized Depression Treatment: Busted

페이지 정보

profile_image
작성자 Cole
댓글 0건 조회 3회 작성일 24-10-29 00:58

본문

Personalized Depression Treatment

coe-2023.pngTraditional therapy and medication do not work for many people who are depressed. A customized treatment could be the solution.

Cue is an intervention platform for digital devices that converts passively collected sensor data from smartphones into personalised micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet only half of those suffering from the condition receive treatment. To improve outcomes, healthcare professionals must be able to recognize and treat patients who are most likely to benefit from certain treatments.

A customized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from specific treatments. They use mobile phone sensors as well as a voice assistant that incorporates artificial intelligence and other digital tools. Two grants totaling more than $10 million will be used to identify the biological and behavioral predictors of response.

The majority of research on predictors for depression treatment effectiveness has been focused on the sociodemographic and clinical aspects. These include demographics such as gender, age and education as well as clinical characteristics like symptom severity, comorbidities and biological markers.

While many of these factors can be predicted from information available in medical records, only a few studies have employed longitudinal data to explore the causes of mood among individuals. Many studies do not take into consideration the fact that mood can differ significantly between individuals. Therefore, it is essential to create methods that allow the determination of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behavior and emotions that are unique to each individual.

The team also created an algorithm for machine learning to create dynamic predictors for the mood of each person's depression. The algorithm integrates the individual characteristics to create a unique "digital genotype" for each participant.

This digital phenotype was correlated with CAT DI scores, a psychometrically validated severity scale for symptom severity. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

alternative depression treatment options is the most common cause of disability around the world1, but it is often untreated and misdiagnosed. In addition the absence of effective interventions and stigma associated with depressive disorders prevent many people from seeking help.

To allow for individualized treatment in order to provide a more personalized treatment, identifying patterns that can predict symptoms is essential. However, the current methods for predicting symptoms depend on the clinical interview which is not reliable and only detects a small number of symptoms related to depression.2

Machine learning is used to blend continuous digital behavioral phenotypes of a person captured through smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of severity of symptoms could improve the accuracy of diagnosis and treatment efficacy for depression. These digital phenotypes are able to capture a variety of unique behaviors and activities, which are difficult to capture through interviews, and allow for continuous, high-resolution measurements.

The study enrolled University of California Los Angeles (UCLA) students experiencing mild to severe depressive symptoms participating in the Screening and Treatment for Anxiety and depression treatment elderly (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care according to the severity of their depression and anxiety treatment near me. Participants who scored a high on the CAT DI of 35 or 65 were assigned online support via an online peer coach, whereas those with a score of 75 patients were referred for psychotherapy in-person.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial characteristics. These included sex, age and education, as well as work and financial status; if they were partnered, divorced or single; the frequency of suicidal thoughts, intentions, or attempts; and the frequency with which they drank alcohol. Participants also scored their level of depression severity on a scale ranging from 0-100 using the CAT-DI. The CAT DI assessment was performed every two weeks for participants who received online support and weekly for those who received in-person care.

Predictors of Treatment Response

Research is focused on individualized treatment for depression. Many studies are focused on finding predictors, which can help doctors determine the most effective medications to treat each patient. Particularly, pharmacogenetics is able to identify genetic variants that determine how the body's metabolism reacts to antidepressants. This allows doctors to select drugs that are likely to work best for each patient, reducing the time and effort in trials and errors, while eliminating any side effects that could otherwise slow progress.

Another approach that is promising is to build prediction models that combine information from clinical studies and neural imaging data. These models can be used to determine the variables that are most predictive of a particular outcome, such as whether a medication can improve symptoms or mood. These models can be used to determine the patient's response to a treatment, which will help doctors to maximize the effectiveness of their treatment.

A new type of research employs machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables and increase predictive accuracy. These models have proven to be useful in the prediction of treatment outcomes like the response to antidepressants. These approaches are gaining popularity in psychiatry, and it is expected that they will become the norm for the future of clinical practice.

In addition to the ML-based prediction models, research into the mechanisms behind depression continues. Recent research suggests that depression is connected to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment for depression will be based upon targeted treatments that restore normal function to these circuits.

One method to achieve this is by using internet-based programs that can provide a more individualized and tailored experience for patients. For instance, one study found that a program on the internet was more effective than standard care in improving symptoms and providing a better quality of life for people suffering from MDD. Furthermore, a randomized controlled study of a personalised approach to depression treatment showed sustained improvement and reduced adverse effects in a significant number of participants.

Predictors of side effects

In the treatment of depression, the biggest challenge is predicting and identifying which antidepressant medications will have very little or no negative side negative effects. Many patients take a trial-and-error approach, with various medications prescribed until they find one that is safe and effective. Pharmacogenetics offers a new and exciting method to choose antidepressant drugs that are more efficient and targeted.

There are a variety of variables that can be used to determine the antidepressant that should be prescribed, such as gene variations, patient phenotypes such as ethnicity or gender and comorbidities. To determine the most reliable and reliable predictors for a particular treatment, randomized controlled trials with larger numbers of participants will be required. This is because the detection of interaction effects or moderators could be more difficult in trials that take into account a single episode of treatment per patient, rather than multiple episodes of treatment over a period of time.

Furthermore the prediction of a patient's reaction to a particular medication will also likely require information about the symptom profile and comorbidities, as well as the patient's previous experience of its tolerability and effectiveness. Currently, only a few easily assessable sociodemographic variables and clinical variables are reliably related to response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to depression treatment is still in its infancy and there are many hurdles to overcome. First, a clear understanding of the genetic mechanisms is essential as well as a clear definition of what is a reliable predictor of treatment response. Ethics such as privacy and the responsible use genetic information must also be considered. In the long-term the use of pharmacogenetics could be a way to lessen the stigma that surrounds mental health alternative treatment for depression and anxiety and improve treatment outcomes for those struggling with depression. As with all psychiatric approaches, it is important to carefully consider and implement the plan. In the moment, it's recommended to provide patients with various depression medications that are effective and urge them to speak openly with their physicians.

댓글목록

등록된 댓글이 없습니다.

TOP
COMPANY

경기 용인 처인구 이동읍 이원로 80번길 20-9
Tel. 031-322-0233
Fax. 031-322-3521
E-mail. kumo@kumo-group.com

Follow us